Intralesional triamcinolone acetonide injection in hypertrophic skin surrounding the percutaneous titanium implant of a bone-anchored hearing aid

van Rijswijk, J B; Mylanus, E
Intralesional triamcinolone acetonide injection in hypertrophic skin surrounding the percutaneous titanium implant of a bone-anchored hearing aid

Abstract

Objective: We present a patient with persistent hypertrophic skin surrounding the percutaneous implant of a bone-anchored hearing aid system, successfully treated with intralesional applied corticosteroids.

Method: Case report and review of the world literature concerning bone-anchored hearing aid implantation and intralesional applied corticosteroids for the treatment of hypertrophic scars and keloids.

Results: Eight weeks after revision surgery to reduce surplus skin and subcutaneous scar tissue overgrowing the abutment, skin and subcutaneous scar tissue overgrowth reoccurred. As an alternative to yet another surgical procedure, the hypertrophic skin was treated with intralesional injections of triamcinolone acetonide. Three weeks after the treatment, a satisfying result was seen, and no subsequent relapse was observed.

Conclusion: To our knowledge, this is the first, photographically well documented case report of a patient with persistent hypertrophic skin surrounding a percutaneous bone-anchored hearing aid implant, successfully treated with intralesional applied corticosteroids.
Intralesional triamcinolone acetonide injection in hypertrophic skin surrounding the percutaneous titanium implant of a bone-anchored hearing aid

J B Van Ruiswijk, E A M Mylanus*

Abstract
Objective: We present a patient with persistent hypertrophic skin surrounding the percutaneous implant of a bone-anchored hearing aid system, successfully treated with intralesional applied corticosteroids.

Method: Case report and review of the world literature concerning bone-anchored hearing aid implantation and intralesional applied corticosteroids for the treatment of hypertrophic scars and keloids.

Results: Eight weeks after revision surgery to reduce surplus skin and subcutaneous scar tissue overgrowing the abutment, skin and subcutaneous scar tissue overgrowth reoccurred. As an alternative to yet another surgical procedure, the hypertrophic skin was treated with intralesional injections of triamcinolone acetonide. Three weeks after the treatment, a satisfying result was seen, and no subsequent relapse was observed.

Conclusion: To our knowledge, this is the first, photographically well documented case report of a patient with persistent hypertrophic skin surrounding a percutaneous bone-anchored hearing aid implant, successfully treated with intralesional applied corticosteroids.

Key words: Bone Anchored Hearing Aids; Implants and Prostheses; Intralesional Injections; Triamcinolone

Introduction
The bone-anchored hearing aid (BAHA) represents an alternative to the conventional bone-conduction hearing aid (fitted to a headband or onto a specially strengthened spectacle). The BAHA system, in which the transducer is fitted onto a percutaneous coupling device attached to a titanium fixture placed in the temporal bone, has both cosmetic and acoustic advantages over the conventional bone conduction hearing aid, and has known quality of life benefits.1

In the early 1980s, Tjellström and Håkansson published the first clinical BAHA studies.2 Over time, the implantation procedure has been simplified. For adults, the standard two-stage surgical procedure for inserting the percutaneous implant into the temporal bone has been converted to a single-stage procedure in which the percutaneous coupling device (abutment) is premounted onto a self-tapping screw fixture. As a result of positive experience with the BAHA for conventional indications, and the low rate of predominantly minor complications,3–5 the indications for BAHA continue to grow, extending to severe unilateral hearing loss and to cases of unilateral conductive or mixed hearing loss which traditionally have been left unaided.6,7

Insertion of the percutaneous implant may sometimes give rise to adverse skin reactions. Several large studies reported an average occurrence of adverse skin reactions in adults of 15 per cent (10–20 per cent), most of which can be successfully treated in an office setting. Implant extrusion is the most severe complication, although rare (average occurrence 5 per cent (2.5–10 per cent)), and may be the result of trauma, inadequate osseo-integration or inflammatory processes.3–5 An important predisposing factor for adverse skin reactions is the mobility of the skin surrounding the abutment. Therefore, a vital part of the surgical procedure is the reduction of subcutaneous tissue so that the skin is sufficiently thin, firmly attached to the underlying periosteum and without hair follicles.8 In some patients, however, independent of the technique used to reduce subcutaneous tissue,9–11 the skin hypertrophies and pushes up against the implant abutment, in some cases even growing over it, jeopardising the accessibility of the abutment for the transducer coupling. If hypertrophic skin persists and does not respond to conservative treatment (e.g. application of antibiotic and corticosteroid ointment), revision surgery is needed. At the department of otorhinolaryngology of the Radboud University Medical Center, approximately 6 per cent of the patients have required revision surgery of the surrounding skin for this indication.

Revision surgery may not be applicable or desirable in some patients, and alternative methods of treatment are required. We present a patient with persistent hypertrophic skin surrounding the percutaneous implant, successfully treated with intralesional applied corticosteroids.

Case report
Eight months after his initial BAHA implant, a 62-year-old man underwent revision surgery to reduce and thin
the surplus of skin and subcutaneous scar tissue overgrowing the abutment. The pre-operative condition is shown in Figure 1.

After local anaesthesia, a straight incision of approximately 3 cm was made, with the percutaneous abutment at the centre of the incision. Both sides of the incision were thinned out, removing all subcutaneous tissue but leaving the periosteum.

Post-operative care consisted of a bolster dressing under a healing cap for one week. Figure 2 shows the post-operative condition directly after removal of the healing cap and bolster dressing.

Despite a good initial result, with the patient being able to wear his BAHA without any problems or complaints, after six to eight weeks the skin and subcutaneous scar tissue overgrowth reoccurred (Figure 3). As an alternative to yet another surgical procedure, the hypertrophic skin was treated with intrallesiional injections of a total of 1 ml of triamcinolone acetonide 40 mg/ml, using a 30-gauge needle on a Luer-lock syringe, without any preceding local anaesthesia. The injection was well tolerated by the patient. After just a few days, he noticed that coupling the BAHA transducer on the abutment became easier.

Three weeks after the triamcinolone treatment, a satisfying result was seen (Figure 4). No relapse was seen over the subsequent six months.

Discussion

The use of triamcinolone acetonide injections for the treatment of hypertrophic scars and keloids has been shown to be
effective in some patients, and has been in use for several decades.\textsuperscript{12,13} In the majority of patients, multiple intralesional injections are needed to obtain the desired clinical effect, i.e. flattening of the lesion and cessation of itching. In the long term, the recurrence rate may rise to 50 per cent.\textsuperscript{12} The main effect of intralesional steroids on the connective tissue of keloids is a decrease in viscosity due to a loss of ground substance.\textsuperscript{13,14} Few complications have been documented, and are limited to local skin changes or pain as a result of the injection. Rarely, Cushing’s syndrome has been described, usually self-limiting. However, in children, features of Cushing’s syndrome may be protracted. Therefore, the dosages of intralesional steroids normally recommended for adults are inappropriate for children.\textsuperscript{15}

- Siting of a percutaneous bone-anchored hearing aid (BAHA) implant may give rise to adverse skin reactions
- This paper describes a patient with persistent hypertrophic skin surrounding the percutaneous implant of his BAHA system, which was successfully treated with intralesional applied corticosteroids
- In order to confirm the effectiveness of this treatment mode, long term results need to be documented in a considerable number of patients

Skin and subcutaneous scar tissue overgrowing the BAHA abutment is a troublesome condition, often causing the patient discomfort and pain, and difficulty in coupling the transducer. Although in some cases conservative treatment may be successful, revision surgery will be required in most patients. The intralesional application of triamcinolone acetonide may prove to be a worthwhile alternative. In our current patient, at the time of writing, no side effects of the treatment have been observed, and the result is satisfactory and sustained. In order to confirm the effectiveness of this treatment mode, long term results will need to be documented in a considerable number of patients.

References
5 van der Pouw CT, Mylanus EA, Cremers CW. Percutaneous implants in the temporal bone for securing a bone conductor: surgical methods and results. \textit{Ann Otol Rhinol Laryngol} 1999; \textbf{108}:532–6
6 Kunst SJW, Leijendeckers JM, Mylanus EAM, Hol MKS, Snik AFM, Cremers CWRJ. BAHA system application for unilateral congenital conductive hearing impairment: audiometric results. Unexpected good results in the aided situation. \textit{Otol Neurotol} 2008, in press
14 Krusche T, Worret WJ. Mechanical properties of keloids in vivo during treatment with intralesional triamcinolone acetonide. \textit{Arch Dermatol Res} 1995; \textbf{287}:289–93

Address for correspondence:
Dr Jeroen B van Rijswijk,
ENT Surgeon,
Stationsweg 22,
3247 BW Dirksland,
The Netherlands.
Fax: +31 18760 7129
E-mail: jeroen@vanryswyk.nl

Dr J B van Rijswijk takes responsibility for the integrity of the content of the paper.
Competing interests: None declared